Analysts are intrested in these 5 stocks: ( (TEM) ), ( (ADBE) ), ( (HELP) ), ( (STZ) ) and ( (SYK) ). Here is a breakdown of their recent ratings and the rationale behind them.
Claim 30% Off TipRanks
New trading tool for TEM bullsTempus AI’s Class A shares have caught fresh attention as analyst Daniel Brennan upgrades TEM from Hold to Buy with a $65 price target after a bruising 50% slide in six months. He argues that fears about AI eroding its data business are overdone, seeing its unique multimodal dataset as increasingly valuable as pharma steps up AI‑driven R&D.
Brennan expects the Insights unit to swing back to positive growth in 2026, potentially beating current forecasts by roughly 10% as backlog converts and demand improves. He also highlights the Genomics franchise, where he sees conservative management volume goals, room for price upside, and regulatory catalysts that could expand Tempus’s total addressable market over the next three to five years.
Adobe is back under the microscope as analyst Nick Altmann initiates coverage on ADBE with a Neutral rating, reflecting a cautiously optimistic stance on its AI strategy. He notes that despite resilient revenue growth and strong margins, the stock has badly lagged peers as investors debate how generative AI will reshape the creative software landscape.
Altmann views Adobe’s Firefly and open‑platform approach as smart moves that could turn AI into a growth driver by expanding the creative market and solving copyright and IP concerns for enterprise users. Still, he sees real competitive and pricing risks from new AI tools and large platforms, and without clearer proof that AI will lift rather than cap Adobe’s earnings power, he prefers to wait on the sidelines despite an attractive valuation versus software peers.
In biotech, Helus Pharma is stepping into the spotlight as analyst Ritu Baral initiates coverage of HELP with a Buy rating and an $8 price target. Her call is built around lead program HLP003, a deuterated psilocin candidate for adjunctive treatment of major depressive disorder, with Phase 3 data expected in late 2026 and a modeled U.S. launch by 2028.
Baral argues that prior Phase 2 results and broad clinical experience with psilocybin meaningfully de‑risk the pivotal trial, supporting her long‑term peak U.S. sales estimate of about $1.3 billion. She believes Helus’s chemistry tweaks could translate into faster onset, more predictable treatment sessions, and better scalability, positioning the company to address significant unmet need in later‑line MDD while also leaving room for out‑of‑pocket demand from motivated patients.
Constellation Brands is edging back into favor as analyst Robert Moskow upgrades STZ to Buy with a $190 price target, signaling renewed confidence ahead of upcoming earnings. His call is part of a broader sector preview, but it underscores a view that the company’s fundamentals can support further upside despite a mixed consumer backdrop.
For investors watching the beverage space, the upgrade suggests Moskow sees Constellation as one of the better‑positioned names among large consumer staples. With the firm consolidating its quarterly outlooks, the fresh Buy rating on STZ stands out as a signal that analysts expect the brewer and distiller to navigate near‑term volatility while continuing to compound shareholder value over time.
Medical‑device giant Stryker also draws a bullish debut as analyst Mike Kratky initiates coverage on SYK with an Outperform (Buy) rating and a $410 price target. He points to Stryker’s track record of double‑digit organic growth and earnings expansion, driven by a powerful commercial engine and steady product innovation across orthopedics and other surgical markets.
Kratky argues that Stryker’s shift toward faster‑growing segments in MedSurg and NeuroTech can extend its outperformance, even as broader MedTech stocks struggle. While a recent cyberattack will weigh on near‑term results, he notes that management’s reaffirmed full‑year guidance reinforces the view that the disruption is temporary and that Stryker’s long‑term growth story remains intact.